---
title: "Evercore ISI Sticks to Their Buy Rating for Revolution Medicines (RVMD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285581650.md"
description: "Evercore ISI analyst Cory Kasimov has reaffirmed a Buy rating for Revolution Medicines (RVMD) with a price target of $200.00. Kasimov, a 5-star analyst, has an average return of 16.5% and a success rate of 56.85%. The overall analyst consensus for Revolution Medicines is a Strong Buy, with an average price target of $176.95."
datetime: "2026-05-07T15:16:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285581650.md)
  - [en](https://longbridge.com/en/news/285581650.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285581650.md)
---

# Evercore ISI Sticks to Their Buy Rating for Revolution Medicines (RVMD)

In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Revolution Medicines, with a price target of $200.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Kasimov is a 5-star analyst with an average return of 16.5% and a 56.85% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Summit Therapeutics, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $176.95 average price target.

### Related Stocks

- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [EVR.US](https://longbridge.com/en/quote/EVR.US.md)
- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report](https://longbridge.com/en/news/286590889.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [US Cancer Clinics Rush to Access Revolutionary Pancreatic Cancer Drug Daraxonrasib](https://longbridge.com/en/news/286405546.md)
- [A Look At Revolution Medicines (RVMD) Valuation After Daraxonrasib Expanded Access Approval](https://longbridge.com/en/news/285222043.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)